EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
17.74
+1.02 (6.10%)
At close: Dec 5, 2025, 4:00 PM EST
17.40
-0.34 (-1.92%)
After-hours: Dec 5, 2025, 6:43 PM EST
EyePoint Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 42.34 | 43.27 | 46.02 | 41.4 | 36.94 | 34.44 | Upgrade
|
| Revenue Growth (YoY) | -7.38% | -5.96% | 11.14% | 12.09% | 7.27% | 69.10% | Upgrade
|
| Cost of Revenue | 203.76 | 133.9 | 68.13 | 57.97 | 36.07 | 23.25 | Upgrade
|
| Gross Profit | -161.42 | -90.63 | -22.11 | -16.56 | 0.87 | 11.19 | Upgrade
|
| Selling, General & Admin | 56.91 | 55.23 | 52.96 | 60.32 | 53.68 | 46.02 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | 2.05 | 2.46 | 2.46 | Upgrade
|
| Operating Expenses | 56.91 | 55.23 | 52.96 | 62.37 | 56.14 | 48.48 | Upgrade
|
| Operating Income | -218.33 | -145.85 | -75.07 | -78.94 | -55.28 | -37.29 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -1.25 | -3.19 | -5.5 | -7.26 | Upgrade
|
| Interest & Investment Income | 12.77 | 15.09 | 6.95 | 2.13 | 0.29 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -205.57 | -130.78 | -69.37 | -80 | -60.48 | -44.49 | Upgrade
|
| Asset Writedown | - | - | - | -20.7 | - | - | Upgrade
|
| Other Unusual Items | - | - | -1.35 | -1.56 | 2.07 | -0.91 | Upgrade
|
| Pretax Income | -205.57 | -130.78 | -70.71 | -102.25 | -58.42 | -45.39 | Upgrade
|
| Income Tax Expense | 0.18 | 0.09 | 0.08 | - | - | - | Upgrade
|
| Net Income | -205.75 | -130.87 | -70.8 | -102.25 | -58.42 | -45.39 | Upgrade
|
| Net Income to Common | -205.75 | -130.87 | -70.8 | -102.25 | -58.42 | -45.39 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 56 | 39 | 37 | 29 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 56 | 39 | 37 | 29 | 13 | Upgrade
|
| Shares Change (YoY) | 35.36% | 44.71% | 4.25% | 29.76% | 124.04% | 23.06% | Upgrade
|
| EPS (Basic) | -3.00 | -2.32 | -1.82 | -2.74 | -2.03 | -3.54 | Upgrade
|
| EPS (Diluted) | -3.00 | -2.32 | -1.82 | -2.74 | -2.03 | -3.54 | Upgrade
|
| Free Cash Flow | -213.59 | -130.28 | -1.61 | -67.16 | -50.25 | -14.8 | Upgrade
|
| Free Cash Flow Per Share | -3.11 | -2.31 | -0.04 | -1.80 | -1.75 | -1.15 | Upgrade
|
| Gross Margin | - | -209.43% | -48.05% | -40.01% | 2.35% | 32.49% | Upgrade
|
| Operating Margin | -515.67% | -337.06% | -163.13% | -190.65% | -149.64% | -108.29% | Upgrade
|
| Profit Margin | -485.96% | -302.43% | -153.84% | -246.97% | -158.15% | -131.82% | Upgrade
|
| Free Cash Flow Margin | -504.48% | -301.06% | -3.49% | -162.19% | -136.04% | -42.97% | Upgrade
|
| EBITDA | -216.25 | -144.31 | -74.6 | -76.49 | -52.51 | -34.64 | Upgrade
|
| EBITDA Margin | - | - | -162.12% | -184.75% | -142.14% | -100.59% | Upgrade
|
| D&A For EBITDA | 2.08 | 1.54 | 0.46 | 2.45 | 2.77 | 2.65 | Upgrade
|
| EBIT | -218.33 | -145.85 | -75.07 | -78.94 | -55.28 | -37.29 | Upgrade
|
| EBIT Margin | - | - | -163.13% | -190.65% | -149.64% | -108.29% | Upgrade
|
| Revenue as Reported | 42.34 | 43.27 | 46.02 | 41.4 | 36.94 | 34.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.